Europe & Asia
phone: +49 (0)941 942 76-100
fax:        +49 (0)941 942 76-780
US & Canada
phone:+1-877-720-GENE (4363)
fax:       +1-416-233-0854

Proprietary GENEART Production Process

GENEART’s optimization and production processes are protected by a large portfolio of own patents, patent applications and in-licensed third parties’ intellectual property rights.


Gene Optimization:    

  • German patent application No. 10 260 805, and foreign patent applications pending under WO2004059556: Method and devices for optimizing a nucleotide sequence for the purpose of expression of a protein
  • German patent application No. 10 2004 037 652, and foreign patent applications pending under WO2006015789: Method for modulating gene expression by modifying the CpG content

 Gene Synthesis, Variant and Library Construction:

  •  U.S. Patent No. 6,472,184: Method for producing nucleic acid polymers
  • License from City of Hope to use the primer extension process to manufacture and sell DNA molecules under US Patent No. 5,750,380
  • License from F. Hoffmann-La Roche Ltd. to practice the polymerase chain reaction process (PCR) to manufacture in Germany and to sell worldwide DNA molecules (European Patent Nos. 0 200 362 and 0 201 184, United States Patent Nos. 4.683.195 and 4.683.202)
  • European Patent No. 1 913 140, German Patent No. 10 2005 037 351, and foreign patent applications pending under WO07017229: Method for carrying out the selective evolution of proteins in vitro
  • European Patent No.1 913 139, German patent application No. 10 2005 037 349, and foreign patent applications pending under WO07017228: Methods for carrying out the selective evolution of proteins in vivo
  • German Patent No. 10 2007 057 802, and foreign patent applications pending under WO09068305: Steganographic embedding of information in coding genes
  • German Patent No. 10 2007 052 344, German patent application No. 10 2009 011 253.7, and foreign patent applications pending under WO09056343: Method for determining frameshift mutations in coding nucleic acids

Subcloning & other Technologies:

  • License of Invitrogen IP Holdings Inc. to use the Gateway® technology under U.S. Patent Nos. 5,888,732, 6,143,557, 6,171,861, 6,270,969, 6,277,608, and 6,720,140, and / or other pending U.S. and foreign patent applications owned by Invitrogen Corporation
  • License of EMD Chemicals Inc. for pTriEx™ 1.1 vector under U.S. Patent Nos. 6,589,783 and/or other pending U.S. and foreign patent applications owned by EMD Chemicals Inc.
  • License of Dyax Inc. to practice the bacteriophage display inventions (U.S. Patent Nos. 5,223,409, 5,403,484, 5,571,698, 5,837,500 and / or other pending U.S. and foreign patent applications) for sale of a SH3 phage display library and for funded customer research   
  • German Patent No. 100 53 781, European Patent No. 1 356 111, and foreign patent applications pending under WO0236791: Nucleus export reporter system
  • European Patent No. 1 240 333, U.S. Patents No. 7,332,588 and 7,323,557, German patent application No. 100 56 747, and foreign Patents and patent applications pending under WO0136614: The genome of the HIV-1 intersubtype (C/B’) and use thereof
  • European Patents No. 1 156 112, 1 282 712, U.S. Patent No. 7,378,515, and foreign Patents and patent applications pending under WO0188141: Synthetic gagpol genes and their uses
  • German patent application No. 10 2004 037 611, and foreign patent applications pending under WO06013103: Inducible gene expression
Print PDF